Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MatchCART: Competitive CD19 CAR-T (CD28 vs CD137)
NCT02685670Phase 2Unknown
- Start
- Feb 2016
- Primary completion
- Dec 2017
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-CD19-TCRz-CD137 CAR-T in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and 2 more. Primary endpoint: Incidence of adverse events defined as dose-limited toxicity at 30 days. Status: unknown.
02
Drugs
anti-CD19-TCRz-CD137 CAR-T
03
Conditions
acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02685670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02685670.